HCW Biologics Requests FDA Meeting for Next-Gen T-Cell Engager, Eyes 2027 Trials
HCWB has more than doubled off its 52-week low of $1.5.
Summary
HCW Biologics has requested a Type B pre-IND meeting with the FDA for its lead candidate HCW11-018b, a tetravalent T-cell engager for solid tumors. The company is on track to initiate clinical trials in the first half of 2027. Preclinical data suggests the drug may overcome limitations of first-generation TCEs, with activity in gynecologic and pancreatic cancers. A streamlined manufacturing process has been developed to produce cGMP material at lower cost. This follows a series of financing and clinical updates, including positive Phase 1 data for another candidate in June. The FDA meeting request marks a concrete step toward the clinic for a program targeting multi-billion-dollar TCE markets.
At the time of this announcement, HCWB was trading at $3.37 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.3M. The 52-week trading range was $1.50 to $44.10. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.